2nd Annual Monoclonal Antibodies Conference 2005
 

================================================== ===================
2nd Annual Monoclonal Antibodies Conference 2005
Latest regulations, technologies, production methods and therapeutics
Dates of the Event: 29th and 30th of June 2005
Workshop Date: 28th of June
Venue: TBC, London
================================================== ===================

**** CONFERENCE BROCHURE AVAILABLE SHORTLY - ORDER YOURS TODAY ****

This conference will provide delegates with an overview of the current
market trends, focusing on the latest policies and regulations surrounding
the market. It will provide a valuable opportunity for researchers to get
together and discuss the hurdles involved in the production process, the
research being carried out in terms of binding sites and targets and the
application of monoclonal antibodies in therapeutics.

THEMES WILL INCLUDE:
- Regulatory update: covering the white paper guidelines and strategies to
handle post approval changes
- Focused research and CASE STUDIES on antibody binding sites, modification
and production
- CASE STUDIES on therapeutic applications of mAb's: focus on cancer
treatments
- CASE STUDIES in R&D- latest products in clinical trials
- CASE STUDIES on how to form successful alliances
- Monoclonal antibodies: future outlook
- CASE STUDIES on the delivery systems for monoclonal antibodies

CONFIRMED SPEAKERS TO DATE
- Dr. Mauricio Maia, Scientist, Genentech
- Dr. Juan Carlos Almagro, Research Scientist, Biology, Florida
International University
- Dr. Brian Hubbard, Associate Director, Process Development, Amgen
- Dr. Lisa A. Marzilli, Principal Scientist I, Wyeth BioPharma
- Dr. Mark Dennis, Senior Scientist, Department of Antibody Engineering,
Genentech
- Dr. Oguz Ersoy, Manager, Monoclonal Antibody Applications, GE Healthcare,
Sweden
- Dr. Uwe Gottschalk, Vice President, Purification Technologies, Sartorius
AG, Germany
- Professor Jan G. J. van de Winkel, Executive Vice President and Chief
Scientific Officer, Genmab
- Dr. David Stover, Head, Oncology Therapeutic Antibodies, Novartis
- Professor Peter Vollmers, Co-founder, Oncomab
- Dr. Roland Carlsson, Vice President Preclinical Research, Bioinvent
- Dr. Bruce A. Keyt, Vice President, Preclinical Development, Abgenix

------------------
WHO SHOULD ATTEND
------------------

- Senior Director, Antibody Discovery
- Senior Scientist, Protein Technology Biosciences
- Associate Director, Biotechnology
- Director, Antibody Technologies
- Group Leader, Biologics
- Director, Protein Engineering & Structure
- Head Bioprocess Research
- Science Base Leader, Biosciences
- Director, Antibody Engineering
- VP, Display Technology
- Senior Director, Immunology Biology
- Director, Antibody Expression
- Head, Expression and Cell Science
- Biologics Manufacturing Development Manager

---------------------
DELEGATE REGISTRATION
---------------------

Places at this event are strictly limited so BOOK YOUR PLACE NOW.
To make a booking on this event, please contact me via phone or email. Book
early to secure a place.

- PRICING -

Attend the:
Two Day conference with interactive workshop (workshop tbc) - ONLY GBP1600
plus VAT
Two Day conference - ONLY GBP1299 plus VAT
Workshop only - ONLY GBP650 plus VAT

- BOOKINGS -

Booking is easy, simply contact Ben Radford on:

Telephone: +44 (0)20 8767 6711
Fax: +44 (0)20 8767 5001
Terms and conditions apply - see below
Email: mailto:[Only registered and activated users can see links. Click Here To Register...]

US FREEPHONE BOOKING HOTLINE
Please call and ask for Jonathan Bowerbank quoting my name on booking.
+1 866 956 3001

B2B Conferences is part of the Visiongain Group



Terms & Conditions
NB - Due to high demand, we do not 'reserve' or 'hold' places - a request
for an invoice to be raised will be treated as an official booking and will
be subject to the cancellation policy as outlined below.
Cancellations/substitutions and name changes: All bookings carry a 50%
liability after the booking has been made, by post fax, email or web. There
will be no refunds for cancellations received on or after one month before
the start of the conference (e.g. cancellation on or after 20th January for
a conference starting on 20th February). If you decide to cancel after this
date the full invoice remains payable. Conference notes, which are available
on the day, will be sent to you. Unfortunately we are not able to transfer
places between conferences and executive briefings. However if you are
unable to attend the event you may make a substitution/name change at any
time as long as we are informed in writing by e-mail, fax or post. Name
changes and substitutions must be from the same company and are not
transferable between companies or countries.

Indemnity: visiongain Ltd reserve the right to change the
conference/executive briefing content, timing, speakers or venue without
notice. The event may be postponed or cancelled due to acts of terrorism,
war, extreme weather conditions, industrial action, acts of God or any event
beyond the control of visiongain Ltd. If such a situation arises we will
endeavour to reschedule the event. However, visiongain Ltd cannot be held
responsible for any cost, damage or expenses, which may be incurred by the
customer as a consequence of the event being postponed or cancelled. We
therefore strongly advise all customers to take out insurance to cover the
cost of the registration, travel and expenses.

To unsubscribe please reply with unsubscribe in the subject line.

Data protection: Visiongain Ltd gathers and manages data in accordance with
the Data Protection Act 1998. Information contained about you may be used to
update you on visiongain Ltd products and services via post, telephone, fax
or email, unless you state otherwise. If you wish your details to be
amended, please send your request to the Database Manager, visiongain Ltd,
40 Tooting High Street, London, SW17 0RG. Alternatively please reply with
unsubscribe in the subject line. Please allow approximately 7 days for your
removal or update request, you may receive additional pieces of
communication from visiongain Ltd during the transitional period, whilst the
changes come into effect.

---